Vivos Therapeutics (NASDAQ:VVOS) Lowered to “Hold” Rating by Alliance Global Partners
Alliance Global Partners downgraded shares of Vivos Therapeutics (NASDAQ:VVOS – Free Report) from a strong-buy rating to a hold rating in a report published on Tuesday,Zacks.com reports. Separately, Ascendiant Capital Markets lowered their price objective on shares of Vivos Therapeutics from $6.60 to $6.20 and set a “buy” rating on the stock in a research […]
Alliance Global Partners downgraded shares of Vivos Therapeutics (NASDAQ:VVOS – Free Report) from a strong-buy rating to a hold rating in a report published on Tuesday,Zacks.com reports. Separately, Ascendiant Capital Markets lowered their price objective on shares of Vivos Therapeutics from $6.60 to $6.20 and set a “buy” rating on the stock in a research […]
